China-based Tasly Pharmaceuticals (SHA: 600535) announced a joint venture (JV) with France’s Mauna Kea Technologies (Paris: MKEA) to commercialize the Cellvizio platform in China and develop it globally for neurology and neurosurgery. The JV will hold exclusive rights to Cellvizio for certain indications in China and global rights for neurological applications.
JV Details
Tasly will invest USD 10 million in cash and hold a majority stake, while Mauna Kea will receive a 44% stake in exchange for technology rights. The JV will manufacture Cellvizio exclusively for the China market.
Technology Profile
Cellvizio’s p/nCLE platform enables subcellular imaging of gastrointestinal mucosa and microvasculature during endoscopy. The device is used for real-time disease monitoring and surgical guidance. Already approved in the US and China, it is installed in multiple Chinese hospitals. Tasly’s commercial network is expected to boost sales, with potential development of new molecular marker combinations.-Fineline Info & Tech
